Vertex Pharmaceuticals Incorporated faces slowing Trikafta/Kaftrio sales and a stock-price divergence with peers. Click for this VRTX earnings update.

Google introduces Gemini 3.1 Pro, a major upgrade with dramatically improved reasoning and problem-solving abilities, designed to deliver deeper insights across apps, workflows, and developer tools.

Semiconductor testing company FormFactor (NASDAQ:FORM) will be reporting earnings this Wednesday after market close. Here’s what to look for. FormFactor beat analysts’ revenue expectations by 1.3% ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.

The average one-year price target for FormFactor (NasdaqGS:FORM) has been revised to $69.36 / share. This is an increase of 19.30% from the prior estimate of $58.14 dated January 11, 2026. The price ...

FormFactor (FORM) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.27 per share a year ago. These figures ...

Sanofi has replaced its CEO Paul Hudson after a series of R&D setbacks at the French pharma, handing the reins to Merck KGaA leader Belén Garijo, M.D., Ph.D.

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As we ...

FormFactor, Inc. has reported past fourth-quarter 2025 results showing revenue of US$215.16 million and net income of US$23.22 million, with both sales and earnings ahead of the prior year and company ...